Acute Biphenotypic Leukemia Clinical Trials

32 clinical trials for Acute Biphenotypic Leukemia across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Personalized NK Cell Therapy in CBT — RECRUITING · PHASE2
• Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant — RECRUITING · PHASE2
• Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia — RECRUITING · PHASE2
• HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant — RECRUITING · PHASE1
• Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms — RECRUITING · PHASE1
• Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation — RECRUITING · PHASE2
• A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies — NOT_YET_RECRUITING · NA
• Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes — ACTIVE_NOT_RECRUITING · PHASE2
• Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting — ACTIVE_NOT_RECRUITING · PHASE2
• Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD — COMPLETED · PHASE2
• Cryopreserved MMUD BM With PTCy for Hematologic Malignancies — WITHDRAWN · PHASE1
• Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm — ACTIVE_NOT_RECRUITING · PHASE1
• HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide — COMPLETED · PHASE2
• Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia — COMPLETED · PHASE2
• Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease — COMPLETED · PHASE2
• Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia — COMPLETED · PHASE2
• Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children — COMPLETED · PHASE2
• Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma — COMPLETED · PHASE2
• Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention — COMPLETED · PHASE3
• Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant — COMPLETED · PHASE2
• Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome — COMPLETED · PHASE1
• Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant — COMPLETED · PHASE2
• Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies — TERMINATED · PHASE2
• CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies — COMPLETED · PHASE1
• Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes — COMPLETED · PHASE2
• Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer — WITHDRAWN · PHASE2
• NK Cells in Cord Blood Transplantation — OTHER · PHASE1
• Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes — COMPLETED · PHASE1
• Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia — TERMINATED · PHASE2
• Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia — TERMINATED · PHASE2
• Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia — COMPLETED · NA

Refine this search